EUVIMEDEUVIMED entdecken
Open Access

Development of a flow cytometric immunoassay using recombinant vascular endothelial growth factor (VEGF)-functionalized poly(ε-caprolactone) microbeads for bevacizumab quantification

Negar Namaei-Ghasemnia iD, Mohammad Rabiee iD, Fatemeh Davami iD, Yeganeh Talebkhan-Garoosi, Mohamad Ghorbani

Advanced Pharmaceutical Bulletin · 12.07.2026

DOI: 10.34172/apb.46777 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Pharmaceutical Bulletin, online erschienen am 12.07.2026. Verfasst von Negar Namaei-Ghasemnia und 4 weiteren Autor:innen. Beteiligte Einrichtung: Biomaterial Group, Department of Biomedical Engineering, Amirkabir University of Technology, Tehran, Iran. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

With the growing research interest in therapeutic monoclonal antibodies (mAbs) and their broad range of applications, the development of reliable analytical approaches for their quantification has become increasingly important. Since, microbead (MB)-based flow cytometric immunoassays have emerged as highly sensitive analytical methods, the aim of this study was to develop and evaluate a flow cytometry-based method using poly(ε-caprolactone) (PCL) MBs to quantify bevacizumab (BVZ) concentration.

Methods

PCL MBs were synthesized through the emulsion/solvent evaporation method and modified by reaction with 1,2-ethylenediamine (EDA) to enable covalent binding of biomolecules. Based on the optimal biomolecule immobilization conditions determined using a model protein, purified recombinant vascular endothelial growth factor (VEGF) protein was immobilized on the surface of amine-functionalized MBs (A-MBs(45)) to capture BVZ, which was then detected using fluorescein isothiocyanate (FITC)-conjugated anti-human IgG antibody in flow cytometry.

Results

The synthesized PCL MBs, with an average diameter of 6.62 ± 0.17 µm, were within the suitable particle size range for immunoassay applications. The optimal aminolysis time was found to be 45 min at 37 °C, and the maximum protein coupling was achieved 5 h post-incubation at pH 8.0. The developed MB-based flow cytometric immunoassay demonstrated the potential to quantify BVZ with a limit of detection (LOD) and limit of quantification (LOQ) of about 6.71 and 22.73 ng mL-1, respectively.

Conclusion

Considering the ease of fabrication and functionalization of PCL MBs under the obtained optimal conditions, along with their capability for analyte detection, these cost-effective analytical platforms may serve as promising candidates for BVZ quantification.

Schlagwörter

Stichwörter der Autor:innen

BevacizumabFlow cytometryMicrobead-based flow cytometric immunoassaysMicrobeadsVascular endothelial growth factor

Autor:innen und Institutionen

  • Biomaterial Group, Department of Biomedical Engineering, Amirkabir University of Technology, Tehran, Iran.
  • Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
  • Department of Molecular and Cellular Sciences, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.

ORCID-Profile: Negar Namaei-Ghasemnia, Mohammad Rabiee, Fatemeh Davami

Zitieren

APA

Namaei-Ghasemnia, N., Rabiee, M., Davami, F., Talebkhan-Garoosi, Y., & Ghorbani, M. (2026). Development of a flow cytometric immunoassay using recombinant vascular endothelial growth factor (VEGF)-functionalized poly(ε-caprolactone) microbeads for bevacizumab quantification. Advanced Pharmaceutical Bulletin. https://doi.org/10.34172/apb.46777

Vancouver

Namaei-Ghasemnia N, Rabiee M, Davami F, Talebkhan-Garoosi Y, Ghorbani M. Development of a flow cytometric immunoassay using recombinant vascular endothelial growth factor (VEGF)-functionalized poly(ε-caprolactone) microbeads for bevacizumab quantification. Advanced Pharmaceutical Bulletin. 2026. doi:10.34172/apb.46777

BibTeX
@article{NamaeiGhasemnia2026,
  author = {Namaei-Ghasemnia, Negar and Rabiee, Mohammad and Davami, Fatemeh and Talebkhan-Garoosi, Yeganeh and Ghorbani, Mohamad},
  title = {Development of a flow cytometric immunoassay using recombinant vascular endothelial growth factor (VEGF)-functionalized poly(ε-caprolactone) microbeads for bevacizumab quantification},
  journal = {Advanced Pharmaceutical Bulletin},
  year = {2026},
  doi = {10.34172/apb.46777}
}
Kostenlos starten →